Cobenfy Stymied

Bristol Myers Squibb’s new $23,000-a-year schizophrenia drug, Cobenfy, faces initial market hurdles as insurers require patients to undergo step therapy. Analysts have lowered expectations for the drug's launch due to these coverage restrictions and patient access challenges.